Početna › Difuzni veliki B-stanični limfom › Virginia
Kliničke studije za Difuzni veliki B-stanični limfom u državi Virginia
17 studija za Difuzni veliki B-stanični limfom traži sudionike na lokacijama u državi Virginia.
Gradovi u državi Virginia
Službeni tekst studije (engleski)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates - Norfolk, Norfolk
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06500273Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- University of Virginia Cancer Center, Charlottesville
- VCU Massey Comprehensive Cancer Center, Richmond
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06649812A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Virginia Commonwealth University Massey Cancer Center, Richmond
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT05006716A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- University of Virginia Cancer Center ( Site 0138), Charlottesville
- Virginia Cancer Institute ( Site 0148), Richmond
- Blue Ridge Cancer Care ( Site 0132), Roanoke
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Virginia Cancer Specialists, PC ( Site 8003), Manassas
- VCU Health Adult Outpatient Pavillion ( Site 0138), Richmond
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06890884Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Virginia Cancer Specialists, PC, Fairfax
- Virginia Oncology Associates - Virginia Beach, Virginia Beach
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06806033A Study of ARC-02 in B-cell NHL
- Massey Cancer Center, Richmond
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 26. kol 2026. · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Virginia Oncology Associates, Norfolk
- Virginia Commonwealth University-Massey Cancer Center, Richmond
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT05826535Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
- VCU Massey Comprehensive Cancer Center, Richmond
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT06536049A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Virginia Health System, Charlottesville
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT04104776A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Virginia Oncology Associates, Norfolk
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. kol 2026. · NCT07188558Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
- University of Virginia Health System, Charlottesville
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 10. srp 2026. · NCT05852717Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- University of Virginia Cancer Center, Charlottesville
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 9. srp 2026. · NCT06015880Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- VCU Massey Comprehensive Cancer Center, Richmond
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. velj 2026. · NCT05633615Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
- Virginia Commonwealth University, Richmond
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 23. sij 2026. · NCT06846463Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 20. lis 2025. · NCT05890352A Study of NX-1607 in Adults With Advanced Malignancies
- University of Virginia, Charlottesville
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2025. · NCT05107674Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.